BioSpace News Archive

ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs) as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, today announced the appointment of Jane F. Barlow, MD, MPH, MBA to the Company’s board of directors (Board).

Skylight Health Group Inc (TSXV:SHG; OTCQX: SHGFF) (“Skylight Health” or the “Company”), has been invited to present at the BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference that will be held on February 17-19, 2021.

The New England Journal of Medicine published the Phase III trial results on Klisyri®, an anti-proliferative agent that inhibits tubulin polymerization and Src kinase signaling, for the topical treatment of actinic keratosis (AK) of the face or scalp Klisyri®, developed by Athenex, received FDA approval in December 2020

Bio-Techne Corporation (NASDAQ:TECH) today announced that Exosome Diagnostics, a Bio-Techne brand, has recently published a paper entitled Exosome-based Liquid Biopsies in Cancer: Opportunities and Challenges (Yu, W et al.) , in the highly rated peer-reviewed journal, Annals of Oncology ( link ).

Avanos Medical, Inc. (NYSE: AVNS) will webcast its conference call discussing financial results and business highlights for the fourth quarter and full-year 2020 on Thursday, Feb. 18 at 9 a.m. ET

Global Cord Blood Corporation announced that, in relation to the non-binding proposal letter dated June 4, 2019 received by the Company’s Board of Directors from Cordlife Group Limited, pursuant to which Cordlife proposed to combine its businesses with that of the Company by way of a statutory merger, the Board and the board of Cordlife have mutually agreed to discontinue any further discussions regarding the Cordlife Proposal and/or the Proposed Transaction.

LHC Group, Inc. (NASDAQ: LHCG) today announced details for the release of its results for the fourth quarter and year ended December 31, 2020.

-- Commercial Launch of XPOVIO® (selinexor) In Expanded Multiple Myeloma Indication Fully Underway Following December 18, 2020 FDA Approval -- -- XPOVIO Net Product Sales of $20.2 Million for Fourth Quarter 2020 and $76.2 Million for the Year 2020; Total Revenues of $35.1 Million for the Fourth Quarter 2020 and $108.1 Million for the Year 2020 --

Cellares Corporation, a biotechnology company focused on revolutionizing cell therapy manufacturing, announced the appointment of Rodney Rietze, Ph.D., to the company’s Advisory Board.

SOPHiA GENETICS, a global leader in Data-Driven Medicine, has appointed Ross Muken as Chief Financial Officer (CFO)